The prevalence and treatment gap in epilepsy in China - An ILAE/IBE/WHO study

被引：174

作者：

Wang, WZ

Wu, JZ

Wang, DS

Dai, XY

Yang, B

Wang, TP

Yuan, CL

Scott, RA

Prilipko, LL

de Boer, HM

Sander, JW

机构：

[1] Beijing Neurosurg Inst, Dept Neuroepidemiol, Beijing 100050, Peoples R China

[2] Harbin Med Coll, Dept Neurol, Harbin, Peoples R China

[3] Ningxia Med Coll, Dept Neurol, Ningxia, Peoples R China

[4] Jiaozuo Peoples Hosp, Jiaozuo, Henan Province, Peoples R China

[5] Yangzhou Med Coll, Dept Neurol, Yangzhou, Peoples R China

[6] UCL, Neurol Inst, London WC1E 6BT, England

[7] WHO, Dept Mental Hlth & Substance Dependence, CH-1211 Geneva, Switzerland

[8] Stichting Epilepsie Instellingen Nederland, Heemstede, Netherlands

来源：

NEUROLOGY | 2003年 / 60卷 / 09期

关键词：

D O I：

10.1212/01.WNL.0000059867.35547.DE

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

The authors carried out a door-to-door survey to determine the prevalence of epilepsy among 55,000 people in China. The lifetime prevalence was 7.0/1000, and 41% of all persons had never received appropriate treatment. The prevalence of active epilepsy was 4.6/1000, and 63% of people with active epilepsy had not received antiepileptic treatment in the week before the survey. Figures for the prevalence and the treatment gap were significantly higher than previous estimates.

引用

页码：1544 / 1545

页数：2

共 9 条

[1] Bringing epilepsy out of the shadows - Wide treatment gap needs to be reduced [J].